GlassScriptPhysician profile
Barry K Feinstein
NPI 1023095411
$23,695.92
in general payments reported to CMS, 2019-2025
36 companies · $4,317 in 2025
The $4,317 reported for 2025 was more than what 82% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,439 · 2020: $1,745 · 2021: $3,190 · 2022: $3,555 · 2023: $3,755 · 2024: $4,695 · 2025: $4,317.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Consulting Fee: $18.39 · Education: $9.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,740.29 |
| Consulting Fee | $18.39 |
| Education | $9.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $5,222.82 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Glaxosmithkline, LLC. | $4,602.62 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Regeneron Healthcare Solutions, INC. | $2,211.09 | 2019-2025 | Dupixent |
| Genentech USA, INC. | $1,732.45 | 2019-2025 | Xolair |
| Csl Behring | $1,729.60 | 2019-2025 | Haegarda, Andembry, Hizentra |
| Optinose US, INC. | $942.39 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $876.41 | 2019-2025 | |
| Grifols USA, LLC | $755.08 | 2019-2025 | Xembify, Prolastin-C Liquid |
| Kaleo, INC. | $670.86 | 2019-2024 | Auvi-Q |
| Genzyme Corporation | $592.26 | 2020-2025 | |
| Incyte Corporation | $468.66 | 2021-2025 | Opzelura |
| Pfizer INC. | $465.34 | 2019-2024 | |
| Amgen INC. | $457.38 | 2021-2025 | Tezspire |
| Teva Pharmaceuticals USA, INC. | $393.16 | 2019-2023 | Airduo Digihaler |
| Ars Pharmaceuticals Operations, INC. | $333.52 | 2025 | Neffy |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barry Feinstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.